ird phase III trial will be conducted with a sample size of N3 = N3(ymin), which depends on an assumed minimal clinical relevant effect (<code>ymin</code>).
The third trial then has to be significant at level <code>alpha</code></p></li>
<li><p>If only one of the two trials is successful and the treatment effect of the other points in opposite direction or
if none of the two trials are successful, then no third trial is performed and the drug development development program is not successful.
In the utility 